Fig. 6

PHF6 possesses clinical significance and correlates with HIF-signature in Bca samples. A Differential analysis based on TCGA-Bca indicates the PHF6 levels in tumor and normal samples and was shown by boxplot. B The relative expression of PHF6 in breast cancer tissues or normal control tissues from the collected ZSH-Bca cohort was analyzed by qRT-PCR (n = 35, P < 0.001). C Representative PHF6 immunohistochemical (IHC) staining in breast cancer tissues and adjacent normal tissues. Scale bar = 200 μm (upper), and 50 μm (lower). D Quantification of PHF6 IHC-scores in tumor and normal samples. E, G Kruskal–Wallis (K-W) test showing the relationships between PHF6 and hazard factors, like lymphatic stages (E), clinicalpathological status (F) and TP-53 mutation (G). H Correlation analysis was conducted to uncover relationships between PHF6 and HIF downstream targets based on TCGA-Bca cohort, including VEGFA, ANGPTL4, AQP1, and LOX. I, J Kaplan-Meir analysis with log-rank test was performed to assess the prognostic value of PHF6 in large Bca samples, including TCGA-Bca cohort (N = 1089, I) and external Meta-Validation Bca cohort (N = 2032, J). *P < 0.05, **P < 0.01, ***P < 0.001